Paper345173
Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings.
Ophthalmology, 1978. Cited by 379 papers, by iCite.
Cite this record
ConductScience Library. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Papers, record 345173. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/345173
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Diabetic Retinopathy | Major topic |
| Light Coagulation | Major topic |
| Argon | |
| Clinical Trials as Topic | |
| Follow-Up Studies | |
| Fundus Oculi | |
| Humans | |
| Photography | |
| Retinal Hemorrhage | |
| Retinal Vessels | |
| Risk | |
| Visual Acuity | |
| Visual Fields | |
| Xenon |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT00000160 | Diabetic Retinopathy Study (DRS) | Background |
Source ClinicalTrials.gov
Cited by139
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 379 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41721853 | The CAPA framework: a conceptual model integrating corrective and preventive strategies for retinal ischemia and neovascularization. | Graefes Arch Clin Exp Ophthalmol | 2026 | https://conductscience.org/library/papers/41721853 | PubMed |
| 41693808 | The Association of Lapses in Diabetic Retinopathy Care with Vision Impairment. | Ophthalmol Sci | 2026 | https://conductscience.org/library/papers/41693808 | PubMed |
| 40016519 | Flow and ischemic changes in retina and choroid across diabetic retinopathy spectrum: a SS-OCTA study. | Eye (Lond) | 2025 | https://conductscience.org/library/papers/40016519 | PubMed |
| 39702673 | Mitigation of AI adoption bias through an improved autonomous AI system for diabetic retinal disease. | NPJ Digit Med | 2024 | https://conductscience.org/library/papers/39702673 | PubMed |
| 39426522 | Association of Neighborhood Socioeconomic Disadvantage with Proliferative Diabetic Retinopathy. | Ophthalmol Retina | 2025 | https://conductscience.org/library/papers/39426522 | PubMed |
| 38983088 | Endothelial to mesenchymal cell transition in diabetic retinopathy: targets and therapeutics. | Front Ophthalmol (Lausanne) | 2023 | https://conductscience.org/library/papers/38983088 | PubMed |
| 38958969 | Tutorial on Biostatistics: Sample Size and Power Calculation for Ophthalmic Studies With Correlated Binary Eye Outcomes. | Invest Ophthalmol Vis Sci | 2024 | https://conductscience.org/library/papers/38958969 | PubMed |
| 38765459 | A Two-Decade Bibliometric Analysis of Laser in Ophthalmology: From Past to Present. | Clin Ophthalmol | 2024 | https://conductscience.org/library/papers/38765459 | PubMed |
| 38526804 | Diabetic Disease of the Eye in Canada: Consensus Statements from a Retina Specialist Working Group. | Ophthalmol Ther | 2024 | https://conductscience.org/library/papers/38526804 | PubMed |
| 38357071 | A Narrative Review of Retinopathy in Diabetic Patients. | Cureus | 2024 | https://conductscience.org/library/papers/38357071 | PubMed |
| 38201340 | Regression of Neovascularization after Panretinal Photocoagulation Combined with Anti-VEGF Injection for Proliferative Diabetic Retinopathy-A Review. | Diagnostics (Basel) | 2023 | https://conductscience.org/library/papers/38201340 | PubMed |
| 37627644 | Oxidative Stress and Its Regulation in Diabetic Retinopathy. | Antioxidants (Basel) | 2023 | https://conductscience.org/library/papers/37627644 | PubMed |
| 37228550 | Spontaneous Resolution of Tractional Retinal Detachment in a Type II Diabetic Patient. | Cureus | 2023 | https://conductscience.org/library/papers/37228550 | PubMed |
| 37008297 | Combination Antivascular Endothelial Growth Factor and Modified Panretinal Photocoagulation in Management of Proliferative Diabetic Retinopathy. | J Vitreoretin Dis | 2020 | https://conductscience.org/library/papers/37008297 | PubMed |
| 37002618 | Building a new regional home for implementation science: Annual Midwest Clinical & Translational Research Meetings. | J Investig Med | 2023 | https://conductscience.org/library/papers/37002618 | PubMed |
| 36975019 | Blood pressure control for diabetic retinopathy. | Cochrane Database Syst Rev | 2023 | https://conductscience.org/library/papers/36975019 | PubMed |
| 36939655 | Anti-vascular endothelial growth factor for proliferative diabetic retinopathy. | Cochrane Database Syst Rev | 2023 | https://conductscience.org/library/papers/36939655 | PubMed |
| 36611897 | Essential Role of Multi-Omics Approaches in the Study of Retinal Vascular Diseases. | Cells | 2022 | https://conductscience.org/library/papers/36611897 | PubMed |
| 36106093 | A Paradigm Shift in the Management Approaches of Proliferative Diabetic Retinopathy: Role of Anti-VEGF Therapy. | Clin Ophthalmol | 2022 | https://conductscience.org/library/papers/36106093 | PubMed |
| 35787271 | Diabetic retinopathy with extensively large area of capillary non-perfusion: characteristics and treatment outcomes. | BMC Ophthalmol | 2022 | https://conductscience.org/library/papers/35787271 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Authors
- Grants
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/345173
GET https://conductscience.org/api/papers/v1/345173/cited_by?page=2